Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

Medicare may begin to cover renal denervation with Medtronic’s Symplicity device by October, which could drive coverage among ...

The catheters shown here are for (from top to bottom) Boston Scientific’s Farapulse, Medtronic’s Affera, Medtronic’s Pulse Select, J&J’s Varipulse, and Abbott’s Volt. [Image courtesy of ...

Looking at the universe of stocks we cover at Dividend Channel, on 12/27/24, Medtronic PLC (Symbol: MDT), DENTSPLY SIRONA Inc (Symbol: XRAY), and Danaher Corp (Symbol: DHR) will all trade ex ...

Medtronic remains a "Buy" due to its undervalued stock, recent product launches, and resolved supply chain issues, despite underperformance over the past 7 months. The company posted solid Q2 ...